Creative Biolabs is excited to greet you at the upcoming international conferences. Meet our team at the 13th Annual World ADC San Diego and the 13th Annual World Multispecific Summit in September (booth number to be updated) for expert consultation on your drug discovery. Shoot an email to arrange an in-person meeting!
An archive of ADCC/CDC-enhanced biobetter antibodies developed by Creative Biolabs' state-of-the-art technology platform.
The clinical efficacy of monoclonal antibodies as cancer therapeutics depends largely on their ability to target tumors and induce functional anti-tumor immune responses. Antibody-dependent cell-mediated cytotoxicity (ADCC) is triggered by the interaction of the Fc portion of the antibody with the Fc receptor on the immune cell. This two-step process uses the response of innate immune cells to provide anti-tumor cytotoxicity. In general, the enhanced anti-tumor cytotoxicity is achieved by targeting effector cells such as NK cells, γδ T cells, macrophages and dendritic cells to enhance the immune response function. Effector cells express Fc receptors on their cell surfaces, mainly CD16 or FcγRIIIa (CD16a). These Fc receptors recognize and bind to the Fc portion of antibodies such as IgG that have bound to the surface of pathogen-infected target cells. Once the Fc receptor binds to the Fc region of IgG, effector cells will release cytokines, such as IFN-γ and cytotoxic molecules, that attack the pathogen to infect target cells.
ADCC is part of the defense mechanism of the adaptive immune system that removes infection or cancer cells. Some monoclonal antibody products are designed to mediate their activity by inducing cell death through the ADCC mechanism and use it as the main mode of action. Increasingly, mAb products are designed to remove or limit the ADCC activity of molecules, so that the determination of the presence of ADCC activity and subsequent quantitative analysis of ADCC activity are key steps in the development and characterization of therapeutic antibodies. Therefore, for most other IgG1 antibodies, the potential to mediate ADCC activity as a secondary or tertiary mechanism of action must be evaluated.
Creative Biolabs has spent time solving the well-known variability problem of ADCC analysis to provide a robust and routinely executed ADCC platform method. According to your requirements, our ADCC analysis can be performed using peripheral blood mononuclear cells (PBMC) from multiple genotype donors, which are specifically harvested on the day of analysis. Our ADCC analysis product portfolio also includes alternative ADCC analyses, which utilize engineered cell lines stably expressing FcγRIIIa receptors to eliminate donor-specific variability and provide a feasible solution for validating these complex analyses.
Our qualified ADCC assays for common targets can be tailored to a range of ADCC effector cells, including:
• NK cells
• γδ T cells
• Dendritic cells
• ADCC Reporter Cell
• Total PBMCs or lymphoid enriched PBMC
• KILR CD16 cells
A range of ADCC bioassay target cell lines including human Raji cells, tumor cell lines are also available. We also offer you a precise vision of customizable solutions based on your requirements.
Please browse the product list below to find the right product for you.
|CAT#||Product Name||Assay Type||Cell Type||Inquiry|
|AD-P001-C||ADCC NF-kB-Luc Reporter Effector Cell Line, Human Jurkat T Lymphocytes||Effector Cell Line|
|AD-P002-C||ADCC NFAT Reporter (Luc) Effector Cell Line, Human Jurkat T Lymphocytes||Effector Cell Line|
|AD-P003-C||ADCC NFAT-CD16 Effector Cell Line, Human Jurkat T Lymphocytes||Effector Cell Line|
|AD-P004-C||ADCC Control Target Cell Line (CD19, CD20, PD-L1), Human Raji Cells||Target Cell Line|
|AD-P005-C||ADCC CTLA-4 Target Cell Line, Human Raji Cells||Target Cell Line|
|AD-P006-C||ADCC hPD-1 Target Cell Line, Human Raji Cells||Target Cell Line|
|AD-P007-C||ADCC hPD-L1 Target Cell Line, Human Raji Cells||Target Cell Line|
|AD-P008-C||ADCC hTIGIT Target Cell Line, Human Raji Cells||Target Cell Line|
|AD-P009-C||ADCC hVISTA Target Cell Line, Human Raji Cells||Target Cell Line|
|AD-P010-C||ADCC CD16 (FcɣRIIIa) Effector Cell Line, Human T Lymphocytes||Effector Cell Line|
|AD-P011-C||ADCP FcγRIIa (H variant) /NFAT Reporter Effector Cell Line, Jurkat T Lymphocytes||Effector Cell Line|
|AD-P012-C||iCrea™ ADCC FcγRIIIa (V) Effector Cell Line, Human Jurkat T Lymphocytes||ADCC Assay||Effector Cell Line|
|AD-P013-C||iCrea™ ADCC CD20 (+) Target Cell Line, Human Raji Cells||ADCC Assay||Target Cell Line|
|AD-P014-C||iCrea™ ADCC CD20 (-) Target Cell Line, Human Raji Cells [Control]||ADCC Assay||Target Cell Line|
|AD-P015-C||iCrea™ ADCC EGFR (+) Target Cell Line, Human HEK293 Cells||ADCC Assay||Target Cell Line|
Biobetter Antibodies Betting on the Future Creative Biolabs Visit
All products and services are for Research Use Only. Do Not use in humans.